S&P 500   3,206.10 (-0.63%)
DOW   26,742.82 (-0.47%)
QQQ   257.12 (-1.45%)
AAPL   384.37 (-1.67%)
MSFT   203.69 (-2.09%)
FB   238.42 (-0.77%)
GOOGL   1,501.09 (-1.04%)
AMZN   2,960.80 (-1.60%)
NVDA   403.26 (-1.43%)
CGC   17.87 (-1.54%)
BABA   243.17 (-2.42%)
MU   50.10 (-0.81%)
GE   7.11 (-0.42%)
TSLA   1,489.73 (-3.64%)
AMD   54.36 (-1.79%)
T   30.29 (+0.90%)
ACB   12.17 (-5.44%)
F   6.84 (+1.48%)
GILD   76.01 (-0.83%)
DIS   119.29 (-1.36%)
NFLX   519.33 (-0.75%)
BAC   24.02 (-2.36%)
BA   181.73 (-3.30%)
S&P 500   3,206.10 (-0.63%)
DOW   26,742.82 (-0.47%)
QQQ   257.12 (-1.45%)
AAPL   384.37 (-1.67%)
MSFT   203.69 (-2.09%)
FB   238.42 (-0.77%)
GOOGL   1,501.09 (-1.04%)
AMZN   2,960.80 (-1.60%)
NVDA   403.26 (-1.43%)
CGC   17.87 (-1.54%)
BABA   243.17 (-2.42%)
MU   50.10 (-0.81%)
GE   7.11 (-0.42%)
TSLA   1,489.73 (-3.64%)
AMD   54.36 (-1.79%)
T   30.29 (+0.90%)
ACB   12.17 (-5.44%)
F   6.84 (+1.48%)
GILD   76.01 (-0.83%)
DIS   119.29 (-1.36%)
NFLX   519.33 (-0.75%)
BAC   24.02 (-2.36%)
BA   181.73 (-3.30%)
S&P 500   3,206.10 (-0.63%)
DOW   26,742.82 (-0.47%)
QQQ   257.12 (-1.45%)
AAPL   384.37 (-1.67%)
MSFT   203.69 (-2.09%)
FB   238.42 (-0.77%)
GOOGL   1,501.09 (-1.04%)
AMZN   2,960.80 (-1.60%)
NVDA   403.26 (-1.43%)
CGC   17.87 (-1.54%)
BABA   243.17 (-2.42%)
MU   50.10 (-0.81%)
GE   7.11 (-0.42%)
TSLA   1,489.73 (-3.64%)
AMD   54.36 (-1.79%)
T   30.29 (+0.90%)
ACB   12.17 (-5.44%)
F   6.84 (+1.48%)
GILD   76.01 (-0.83%)
DIS   119.29 (-1.36%)
NFLX   519.33 (-0.75%)
BAC   24.02 (-2.36%)
BA   181.73 (-3.30%)
S&P 500   3,206.10 (-0.63%)
DOW   26,742.82 (-0.47%)
QQQ   257.12 (-1.45%)
AAPL   384.37 (-1.67%)
MSFT   203.69 (-2.09%)
FB   238.42 (-0.77%)
GOOGL   1,501.09 (-1.04%)
AMZN   2,960.80 (-1.60%)
NVDA   403.26 (-1.43%)
CGC   17.87 (-1.54%)
BABA   243.17 (-2.42%)
MU   50.10 (-0.81%)
GE   7.11 (-0.42%)
TSLA   1,489.73 (-3.64%)
AMD   54.36 (-1.79%)
T   30.29 (+0.90%)
ACB   12.17 (-5.44%)
F   6.84 (+1.48%)
GILD   76.01 (-0.83%)
DIS   119.29 (-1.36%)
NFLX   519.33 (-0.75%)
BAC   24.02 (-2.36%)
BA   181.73 (-3.30%)
Log in

LON:TILSTiziana Life Sciences Share Price, Forecast & News

GBX 157
+7.00 (+4.67 %)
(As of 07/16/2020 12:21 PM ET)
Add
Compare
Today's Range
148.55
Now: GBX 157
165
50-Day Range
85
MA: GBX 103.64
139
52-Week Range
23.50
Now: GBX 157
172.50
Volume467,628 shs
Average Volume4,999 shs
Market Capitalization£261.26 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Tiziana Life Sciences Plc, a clinical stage biotechnology company, focuses on the discovery and development of molecules and related diagnostics to treat diseases in oncology and immunology in the United Kingdom. The company's product pipeline includes Foralumab (TZLS-401), a human anti-CD3 monclonal antibody for the treatment of autoimmune and inflammatory diseases, such as non-alcoholic steatohepatitis, Crohn's disease, multiple sclerosis, type-1 diabetes, inflammatory bowel diseases, psoriasis, and rheumatoid arthritis; and Milciclib (TZLS-201), which is an orally bioavailable, small molecule inhibitor of cyclin-dependent kinases and Src family kinases for the treatment of hepatocellular carcinoma. It also develops TZLS-501, a human anti-interleukin-6 receptor monoclonal antibody that is in pre-clinical development. The company was founded in 2013 and is headquartered in London, the United Kingdom. Tiziana Life Sciences Plc is a subsidiary of Planwise Group Limited.
Read More
Tiziana Life Sciences logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 1.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.51 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+44-20-74952379

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Cash FlowGBX 0.14 per share
Book ValueGBX (4) per share

Profitability

Miscellaneous

Employees10
Market Cap£261.26 million
Next Earnings DateN/A
OptionableNot Optionable

Receive TILS News and Ratings via Email

Sign-up to receive the latest news and ratings for TILS and its competitors with MarketBeat's FREE daily newsletter.

Tiziana Life Sciences (LON:TILS) Frequently Asked Questions

How has Tiziana Life Sciences' stock been impacted by COVID-19 (Coronavirus)?

Tiziana Life Sciences' stock was trading at GBX 85 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, TILS shares have increased by 84.7% and is now trading at GBX 157. View which stocks have been most impacted by Coronavirus.

How were Tiziana Life Sciences' earnings last quarter?

Tiziana Life Sciences PLC (LON:TILS) announced its quarterly earnings data on Thursday, June, 18th. The biotechnology company reported ($5.40) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($5.00) by $0.40. View Tiziana Life Sciences' earnings history.

Has Tiziana Life Sciences been receiving favorable news coverage?

Press coverage about TILS stock has been trending positive this week, InfoTrie reports. The research group identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Tiziana Life Sciences earned a media sentiment score of 2.1 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the next several days. View the latest news about Tiziana Life Sciences.

Who are some of Tiziana Life Sciences' key competitors?

What other stocks do shareholders of Tiziana Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tiziana Life Sciences investors own include Synergy Pharmaceuticals (SGYP), ServiceNow (NOW), Broadcom (AVGO), Dropbox (DBX), Enterprise Products Partners (EPD), Franco Nevada (FNV), Micron Technology (MU), RingCentral (RNG), Tesla (TSLA) and Slack (WORK).

Who are Tiziana Life Sciences' key executives?

Tiziana Life Sciences' management team includes the following people:
  • Mr. Gabriele Marco Antonio Cerrone M.B.A., MBA, Founder & Exec. Chairman (Age 47)
  • Dr. Kunwar Shailubhai, CEO, Chief Scientific Officer & Exec. Director (Age 61)
  • Dr. Andrea Brancale, Scientific Founder
  • Mr. Richard Clarkson Ph.D., Scientific Founder
  • Mr. Andrew Westwell Ph.D., Scientific Founder

What is Tiziana Life Sciences' stock symbol?

Tiziana Life Sciences trades on the London Stock Exchange (LON) under the ticker symbol "TILS."

How do I buy shares of Tiziana Life Sciences?

Shares of TILS and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Tiziana Life Sciences' stock price today?

One share of TILS stock can currently be purchased for approximately GBX 157.

How big of a company is Tiziana Life Sciences?

Tiziana Life Sciences has a market capitalization of £261.26 million. Tiziana Life Sciences employs 10 workers across the globe.

What is Tiziana Life Sciences' official website?

The official website for Tiziana Life Sciences is www.tizianalifesciences.com.

How can I contact Tiziana Life Sciences?

Tiziana Life Sciences' mailing address is 3rd Fl, 11-12 St. James's Square, LONDON, SW1Y 4LB, United Kingdom. The biotechnology company can be reached via phone at +44-20-74952379.

This page was last updated on 7/16/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.